Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: A disproportionality analysis

Drug Safety

Volumn 35, Issue 6, 2012, Pages 507-518

  Shamloo, Behrooz K ^a   Chhabra, Pankdeep ^b   Freedman, Andrew N ^c   Potosky, Arnold ^d   Malin, Jennifer ^e   Smith, Sheila Weiss ^b  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Adverse drug reactions; Adverse reaction monitoring; Antineoplastics; Arrhythmias; Autoimmune disorders; Bevacizumab; Cardiovascular disorders; Colon cancer; Conduction disorders; Electrolytes; Gastrointestinal disorders; Necrotising fasciitis; Neurological disorders; Pharmacovigilance; Pneumonitis; Postmarketing surveillance; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINATE CALCIUM; IRINOTECAN; OXALIPLATIN;

ADOLESCENT; ADRENAL DISEASE; ADULT; AGED; AORTA ANEURYSM; AORTA DISSECTION; AORTA RUPTURE; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLADDER PERFORATION; CALCIUM BLOOD LEVEL; CAPILLARY LEAK SYNDROME; CHI SQUARE TEST; CLINICAL EVALUATION; COLON OBSTRUCTION; CONGENITAL MALFORMATION; CONTROLLED STUDY; DATA BASE; DRUG SURVEILLANCE PROGRAM; DUODENUM OBSTRUCTION; ELECTROLYTE DISTURBANCE; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GLOMERULONEPHRITIS; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RIGHT VENTRICLE EJECTION FRACTION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPOPHOSPHATEMIA; INTRACRANIAL HYPOTENSION; INTUSSUSCEPTION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LIVER ATROPHY; LIVER CIRRHOSIS; LIVER ISCHEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOTOR NEUROPATHY; NECROTIZING FASCIITIS; NERVE DEGENERATION; NEUROLOGIC DISEASE; PHOSPHATE BLOOD LEVEL; PNEUMONIA; PORTAL HYPERTENSION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETINA MACULA AGE RELATED DEGENERATION; SENSITIVITY ANALYSIS; SENSORY NEUROPATHY; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SODIUM BLOOD LEVEL; STATISTICAL SIGNIFICANCE; SUDDEN DEATH; TAKOTSUBO CARDIOMYOPATHY; THROMBOCYTE COUNT; VASCULAR DISEASE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DATABASES, FACTUAL; HUMANS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861381471     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11597600-000000000-00000     Document Type: Article

References (38)

1. US FDA. Bevacizumab label: U.S. BL 125085/169 Amendment: Bevacizumab, Genentech, Inc. 2009 [online]. Available from URL: http://www.accessdata.fda. gov/drugsatfda-docs/label/2009/125085s0169lbl.pdf [Accessed 2012 Apr 30]
2. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006 Nov; 90 (11): 1344-9 (Pubitemid 44702055)
3. Garg S, Brod R, Kim D, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Clin Experiment Ophthalmol 2008 Apr; 36 (3): 252-6 (Pubitemid 351560274)
4. US FDA. New molecular entity postmarketing safety evaluation pilot program final report [online]. Available from URL: http://www.fda.gov/Drugs/ DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ucm185252. htm [Accessed 2012 Apr 30]
5. MedDRA. Medical Dictionary for Regulatory Activities [online]. Available from URL: http://www.meddramsso. com/public-about-meddra.asp [Accessed 2012 Apr 30]
6. Deshpande G, Gogolak V, Weiss Smith SR. Data mining in drug safety review of published threshold criteria for defining signals of disproportionate reporting. Pharm Med 2010; 24: 37-43
7. Wong LJ, Desai RU, Jain A, et al. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 2008 Oct; 28 (8): 1151-8
8. Microsoft Excel. 2007 ed. Redmond (WA): Microsoft Corporation, 2007
9. Brown-Glaberman U, Swart R, Dragovich T, et al. Hepatic injury associated with bevacizumab use in metastatic breast and colon cancers: a review of two cases. Commun Oncol 2008; 5: 539-42
10. Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009 Jan; 7 (1): 171-81
11. Gamboa EO, Rehmus EH, Haller N. Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer. Clin Colorectal Cancer 2010 Jan; 9 (1): 55-8
12. Usui K, Katou Y, Furushima K, et al. Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients. Jpn J Clin Oncol 2011 Apr; 41 (4): 498-502
13. Graham CH, Rivers J, Kerbel RS, et al. Extent of vascularization as a prognostic indicator in thin(0.76 mm) malignant melanomas,Am J Pathol, 1994, Sep, 145, 3, 510-4. (Pubitemid 24285957)
14. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 1996 Jun; 15 (2): 165-76 (Pubitemid 26236114)
15. Zhang HT, Craft P, Scott PA, et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995 Feb 1; 87 (3): 213-9
16. Loupakis F, Ruzzo A, Salvatore L, et al. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 2011; 11: 247
17. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 Jan 11; 356 (2): 115-24 (Pubitemid 46089672)
18. Friehs I, Margossian RE, Moran AM, et al. Vascular endothelial growth factor delays onset of failure in pressureoverload hypertrophy through matrix metalloproteinase activation and angiogenesis. Basic Res Cardiol 2006 May; 101 (3): 204-13
19. Cho DH, Choi YJ, Jo SA, et al. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgammaindependent signaling pathways. J Biol Chem 2004 Jan 23; 279 (4): 2499-506 (Pubitemid 38114233)
20. White AJ, LaGerche A, Toner GC, et al. Apical ballooning syndrome during treatment with a vascular endothelial growth factor receptor antagonist. Int J Cardiol 2009 Jan 24; 131 (3): e92-4
21. Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998 Jun 1; 101 (11): 2567-78 (Pubitemid 28270451)
22. Papapetropoulos A, Garcia-Cardena G, Madri JA, et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997 Dec 15; 100 (12): 3131-9 (Pubitemid 28022851)
23. Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 1999 Nov 12; 274 (46): 33057-63 (Pubitemid 129535347)
24. Ziche M, Morbidelli L, Choudhuri R, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factorinduced angiogenesis. J Clin Invest 1997 Jun 1; 99 (11): 2625-34 (Pubitemid 27259809)
25. Rastaldo R, Pagliaro P, Cappello S, et al. Nitric oxide and cardiac function. Life Sci 2007 Aug 16; 81 (10): 779-93 (Pubitemid 47332516)
26. Kubota I, Han X, Opel DJ, et al. Increased susceptibility to development of triggered activity in myocytes from mice with targeted disruption of endothelial nitric oxide synthase. J Mol Cell Cardiol 2000 Jul; 32 (7): 1239-48
27. Levy BI, Ambrosio G, Pries AR, et al. Microcirculation in hypertension: a new target for treatment? Circulation 2001 Aug 7; 104 (6): 735-40 (Pubitemid 32738532)
28. Genentech, Weill Medical College of Cornell University. Pre-operative chemotherapy plus bevacizumab with early salvage therapy based on PET assessment of response in patients with locally advanced but resectable gastric and GEJ adenocarcinoma [ClinicalTrials.gov identifier NCT 00737438]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00737438?term=NCT00737438&rank=1 [Accessed 2012 Apr 30]
29. Genentech, Eisai Inc. Gliadel, XRT, Temodar, Avastin followed by Avastin, Temodar for newly diagnosed glioblastoma multiforme (GBM) [ClinicalTrials.gov identifier NCT01186406. US National Institutes of health, Clinical-Trials.gov [online] Available from URL: http://clinical trials.gov/ct2/show/NCT01186406? term=NCT01186406& rank=1 [Accessed 2012 Apr 30]
30. Lee SH, Kim JG, Park JY, et al. Effect and mechanism of vascular endothelial growth factor on endothelial nitric oxide synthase expression in aortic endothelial cells. J Korean Diabetes Assoc 2002; 26 (5): 396-404
31. Mourad JJ, Le Jeune S. Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. J Hypertens Suppl 2008 Sep; 26 (3): S7-13
32. Vogt BA, Birk PE, Panzarino V, et al. Aortic dissection in young patients with chronic hypertension. Am J Kidney Dis 1999 Feb; 33 (2): 374-8 (Pubitemid 29072243)
33. Shimizu H, Miyazaki M, Wakabayashi Y, et al. Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. J Hepatol 2001 May; 34 (5): 683-9 (Pubitemid 32488783)
34. Reynaert H, Chavez M, Geerts A. Vascular endothelial growth factor and liver regeneration. J Hepatol 2001 May; 34 (5): 759-61 (Pubitemid 32488793)
35. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007 Aug 15; 99 (16): 1232-9 (Pubitemid 47299901)
36. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 Jun 3; 350 (23): 2335-42 (Pubitemid 38702844)
37. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005 Jun 27; 165 (12): 1363-9 (Pubitemid 40973418)
38. US FDA. Guidance for industry. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. March 2005 [online]. Available from URL: Guidance for industry Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment [Accessed 2012 Apr 17]